RGD

OcuTerra Announces Topline Data from Phase 2 DR:EAM Trial Evaluating Nesvategrast (OTT166 5%) for Patients with Diabetic Retinopathy

Retrieved on: 
Thursday, March 14, 2024
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Diabetes, Clinical Trials, RGD, Disease, Patient, Kro (character), Clinical trial, Therapy, Data, Diabetic retinopathy, DRSS, Pharmaceutical industry

Nesvategrast (OTT166 5%) was shown to be safe and well tolerated, meeting its primary safety endpoint.

Key Points: 
  • Nesvategrast (OTT166 5%) was shown to be safe and well tolerated, meeting its primary safety endpoint.
  • “We are disappointed that the topline data on nesvategrast from our Phase 2 DR:EAM clinical trial did not demonstrate a statistically significant impact on severity or progression of diabetic retinopathy,” said Kerrie Brady, CEO and President of OcuTerra.
  • However, the data failed to demonstrate a statistically significant improvement on the diabetic retinopathy severity scale (DRSS) for patients treated with nesvategrast compared to the placebo group, the primary efficacy endpoint.
  • Data also did not show nesvategrast to have significant impact on the progression of disease as measured by DRSS, a key secondary endpoint.

OcuTerra Therapeutics Announces Last Patient Completes Final Visit in Nesvategrast (OTT166) Eye Drop Phase 2 DR:EAM Clinical Trial in Diabetic Retinopathy

Retrieved on: 
Wednesday, January 3, 2024
Biotechnology, Diabetes, Pharmaceutical, Health, DRSS, RGD, DR, Diabetic retinopathy, Paratriathlon, Injection, Disease, Therapy, Clinical trial, PDR, Patient

Nesvategrast, OcuTerra’s novel, selective RGD integrin inhibitor delivered via eye drop, is being developed as a possible treatment for the millions of patients with diabetic retinopathy who currently have no active, non-invasive therapies approved for this potentially devastating disease.

Key Points: 
  • Nesvategrast, OcuTerra’s novel, selective RGD integrin inhibitor delivered via eye drop, is being developed as a possible treatment for the millions of patients with diabetic retinopathy who currently have no active, non-invasive therapies approved for this potentially devastating disease.
  • These data will show the percentage of patients that have a ≥2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) when treated with nesvategrast vs. placebo.
  • The 24-week study enrolled 225 adult patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR) with minimal vision loss.
  • We are excited to begin planning the next phase of development for nesvategrast.”

Sensata Launches First A2L Leak Detection Sensor Certified for Multiple HVAC Refrigerants

Retrieved on: 
Thursday, October 26, 2023
Technology, Engineering, Architecture, Utilities, Manufacturing, Other Construction & Property, Energy, Commercial Building & Real Estate, Construction & Property, Building Systems, Other Technology, HVAC, Hardware, Other Manufacturing, RGD, GWP, NYSE, Hydrofluorocarbon, HFC, R32, Carbon dioxide, Kigali Amendment, Montreal, Certification, Atmosphere, Original equipment manufacturer, UL, Air conditioning, Multimedia, Life expectancy, HFO, CO2, Heat, Montreal Protocol, Gas, Climate, Ventilation, Refrigeration, Heating, ventilation, and air conditioning, Propane

Sensata Technologies (NYSE: ST), today announced the launch of the Sensata Resonix™ RGD sensor, the first leak detection sensor with UL certification for multiple A2L refrigerant gases used in heating, ventilation, and air conditioning (HVAC) equipment.

Key Points: 
  • Sensata Technologies (NYSE: ST), today announced the launch of the Sensata Resonix™ RGD sensor, the first leak detection sensor with UL certification for multiple A2L refrigerant gases used in heating, ventilation, and air conditioning (HVAC) equipment.
  • The new leak detection sensors support HVAC manufacturers’ transition to refrigerants with a lower global warming impact.
  • View the full release here: https://www.businesswire.com/news/home/20231026082973/en/
    Sensata’s Resonix™ RGD sensor detects potential A2L refrigerant leaks in HVAC equipment to help enable a global shift away from potent greenhouse gas refrigerants.
  • (Photo: Business Wire)
    Sensata’s Resonix™ RGD sensors leverage patented gas detection technology to meet the needs of HVAC manufacturers using new hydrofluoroolefin (HFO) refrigerants as part of a global shift away from hydro-fluorocarbon (HFC) refrigerants.

Reunion Gold Announces C$70 Million Bought Deal Financing

Retrieved on: 
Monday, September 18, 2023
BMO Capital Markets, Indian stock exchange, NOT, FOR, RGD, Person, Sale, WIRE, Offering, NEWS, Security (finance)

LONGUEUIL, Québec, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Gold Corporation (TSXV: RGD; OTCQX: RGDFF) (the “Company”) has announced today that it has entered into an agreement with BMO Capital Markets, on behalf of a syndicate of underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a “bought deal” basis, 152,200,000 common shares in the capital of the Company (the “Common Shares”), at a price of C$0.46 per Common Share for gross proceeds of approximately C$70 million (the “Offering”). BMO Capital Markets and SCP Resource Finance will act as co-lead underwriters for this Offering, with BMO Capital Markets acting as sole bookrunner. The Company has granted the Underwriters an option, exercisable at the Offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the Offering to cover over-allotments, if any. The Offering is expected to close on or about September 26, 2023 and is subject to the Company receiving all necessary regulatory approvals.

Key Points: 
  • BMO Capital Markets and SCP Resource Finance will act as co-lead underwriters for this Offering, with BMO Capital Markets acting as sole bookrunner.
  • The Company has granted the Underwriters an option, exercisable at the Offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the Offering to cover over-allotments, if any.
  • The Offering is expected to close on or about September 26, 2023 and is subject to the Company receiving all necessary regulatory approvals.
  • The Company intends to use the net proceeds from the Offering for continued advancement of the Company’s Oko West Project in Guyana and for general corporate purposes.

OcuTerra President and CEO Kerrie Brady Named to 2023 PharmaVoice 100 List of Most Inspiring Leaders

Retrieved on: 
Tuesday, September 19, 2023
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Clinical trial, Diabetic retinopathy, Therapy, MD, Industry Dive, Patient, RGD, Disease, Pharmaceutical industry, Medical device

A prestigious honor in the life sciences industry for nearly 20 years, the PharmaVoice 100 recognizes leaders who have been instrumental in propelling the industry forward and in uplifting employees and patients.

Key Points: 
  • A prestigious honor in the life sciences industry for nearly 20 years, the PharmaVoice 100 recognizes leaders who have been instrumental in propelling the industry forward and in uplifting employees and patients.
  • Since joining the company, Ms. Brady has led numerous company milestones including:
    Securing $35 million in Series B fundraising to support the continued clinical development of OTT166.
  • Initiating and reaching full enrollment for the company’s Phase 2 DR:EAM clinical trial evaluating OTT166 in diabetic retinopathy.
  • “Throughout my career, I’ve been motivated by the potential to translate groundbreaking science into life-changing therapeutics for patients not adequately served by currently available treatments,” said Ms. Brady.

OcuTerra Completes Enrollment in Phase 2 DR:EAM Clinical Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathy

Retrieved on: 
Tuesday, July 18, 2023
Health, Diabetes, General Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Retina, Thomas Jefferson University, Clinical trial, DR, DRSS, Diabetic retinopathy, Wills Eye Hospital, RGD, ClinicalTrials.gov, Synthetic control method, Patient, Engineering, PDR, Principal, Paratriathlon, Therapy, Safety, Disease, Pharmaceutical industry, Medical device, Ophthalmology

“With limited therapeutic options for the treatment of DR on the market, we recognize an immense need for a non-invasive, earlier intervention.

Key Points: 
  • “With limited therapeutic options for the treatment of DR on the market, we recognize an immense need for a non-invasive, earlier intervention.
  • The trial enrolled 225 adult patients who were randomly assigned one of two doses of OTT166 or to one of two control groups receiving vehicle.
  • OTT166 is a small molecule RGD integrin inhibitor delivered topically in the form of an eye drop and is purpose-engineered to distribute to the retina in therapeutic concentrations.
  • “This is an essential milestone for the development of a treatment that could benefit millions of patients with DR.”

DuPont Unveils Cutting-Edge Sealing Solutions for Oil & Gas Industry at CIPPE 2023

Retrieved on: 
Wednesday, May 31, 2023
Carbon, HPHT, Exhibition, DuPont, Electronics, Temperature, RGD, NYSE, Cobham Technical Services, Development, International Petroleum Exposition, Destroyed Russian military equipment exhibition, CCUS, Natural gas

This marks the first time that DuPont will exhibit at the event where it will introduce its cutting-edge solutions, including DuPont™ Kalrez® perfluoroelastomer parts and DuPont™ Vespel® parts and shapes for the oil and gas industry.

Key Points: 
  • This marks the first time that DuPont will exhibit at the event where it will introduce its cutting-edge solutions, including DuPont™ Kalrez® perfluoroelastomer parts and DuPont™ Vespel® parts and shapes for the oil and gas industry.
  • The exhibition will showcase two major product lines enabling energy, oil, and gas solutions, including:
    DuPont™ Kalrez® perfluoroelastomer parts, elastomeric sealing solutions engineered for mission-critical applications, and
    DuPont™ Vespel® parts and shapes that enable high-performance sealing in demanding industrial operating environments.
  • Huang Hui, Technical Service & Development Engineer-Kalrez®, will demonstrate how DuPont™ Kalrez® OG193 elastomers help to solve demanding energy and oil & gas sealing challenges.
  • DuPont is ready to partner with the oil & gas industry to provide sealing solutions for the most demanding applications with Kalrez® elastomers and Vespel® parts and shapes.

OTC Markets Group Welcomes Reunion Gold Corporation to OTCQX

Retrieved on: 
Monday, April 3, 2023
OTCQX, Guiana Shield, RGD, OTC, Gold, Cryptocurrency, Financial adviser

NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Reunion Gold Corporation (TSX-V: RGD; OTCQX: RGDFF), a gold explorer in the Guiana Shield, South America, has qualified to trade on the OTCQX® Best Market.

Key Points: 
  • NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Reunion Gold Corporation (TSX-V: RGD; OTCQX: RGDFF), a gold explorer in the Guiana Shield, South America, has qualified to trade on the OTCQX® Best Market.
  • Reunion Gold Corporation upgraded to OTCQX from the OTCQB® Venture Market.
  • Reunion Gold Corporation begins trading today on OTCQX under the symbol “RGDFF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com .
  • “We are pleased to reach the milestone of trading on OTCQX, which is the highest market tier of the OTC markets,” stated Rick Howes, the CEO of Reunion Gold.

OcuTerra to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 22, 2022
Optical, Health, Clinical Trials, Ophthalmology, Diabetic retinopathy, Severe cognitive impairment, Retina, Therapy, Conference, MS, VEGF, Disease, Eye, MBA, RGD, Cantor, Patient, Pharmaceutical industry, Bachelor of Pharmacy

OcuTerra Therapeutics, Inc. (OcuTerra), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of watch-and-wait does not prevent or control the progression of disease, today announced the companys participation in two upcoming investor conferences.

Key Points: 
  • OcuTerra Therapeutics, Inc. (OcuTerra), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of watch-and-wait does not prevent or control the progression of disease, today announced the companys participation in two upcoming investor conferences.
  • OcuTerra CEO & President Kerrie Brady, BPharm, MS, MBA, will give a fireside chat at BTIGs Ophthalmology Day on November 29.
  • Ms. Brady will also participate in the ophthalmology panel at Cantor Fitzgeralds Medical and Aesthetic Dermatology & Ophthalmology Conference.
  • OcuTerra Therapeutics, Inc. is developing innovative drugs for ophthalmic diseases for which the current standard of care does not prevent or control the [early] progression of disease.

OcuTerra Reports Publication of OTT166 Safety and Biological Activity Data from Phase 1b Study in Diabetic Eye Disease

Retrieved on: 
Wednesday, October 19, 2022
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Diabetes, Clinical Trials, Blood, DME, ClinicalTrials.gov, OCT, Female, Disease, Therapy, Biological activity, US1, Growth, Diabetic retinopathy, RGD, Eye surgery, Patient, Severe cognitive impairment, Eye, Treatment, CRT, Diabetes, Retinopathy, Toxicity, Research, Adult, Safety, Ageing, DR, American Academy, Injection, Clinical trial, DRSS, OCB, VEGF, Laser, Male, American Academy of Ophthalmology, Pharmaceutical industry, Ophthalmology, Retina

The data show that OTT166 eyedrops were well-tolerated and demonstrated biological activity, warranting further evaluation for the treatment of diabetic eye disease.

Key Points: 
  • The data show that OTT166 eyedrops were well-tolerated and demonstrated biological activity, warranting further evaluation for the treatment of diabetic eye disease.
  • Based on these findings, the Phase 2 DR:EAM study is underway to evaluate safety and efficacy of OTT166 in diabetic retinopathy.
  • In early clinical trials in patients with diabetic retinal disease, OTT166 eye drops have demonstrated preliminary evidence of tolerability and biological activity.
  • The Phase 1b DR/DME clinical trial (NCT02914613) was a prospective, randomized, double-masked, first-in-human study of OTT166 (formerly designated SF0166) eye drops in patients with DR/DME, i.e.